Patents Issued in October 19, 2017
  • Publication number: 20170296612
    Abstract: The present invention relates to a combination of valerian root extract and lavender oil for treating of sleep disorders, as well as to a combination of preparation comprising valerian root extract and lavender oil.
    Type: Application
    Filed: June 10, 2015
    Publication date: October 19, 2017
    Inventors: Wilfried Dimpfel, Michael Nöldner
  • Publication number: 20170296613
    Abstract: The invention provides a dermatological kit comprising a first container comprising a first composition and a second container comprising a second composition, different from the first composition, wherein the first composition comprises trichloro-acetic acid and a hibiscus acid, wherein the second composition comprises a material of Mauritia flexuosa origin and a hibiscus acid, and wherein the second composition has a sun protection factor (SPF) of at least 15.
    Type: Application
    Filed: October 6, 2015
    Publication date: October 19, 2017
    Inventor: Maikel HENDRIKS
  • Publication number: 20170296614
    Abstract: The present invention relates to the field of herbal compositions. In particular, the present invention is directed to an Improved Herbal Extract Composition comprising a Melissa species extract, an Avena species extract, a Tilia species extract and a unique blend of citrus components. The composition can further comprise at least one additional extract of a plant such as Citrus species, Crataegus species, Panax species, and Lavendula species. The herbal extract composition is useful in numerous ingestible forms including an extract concentrate for food and beverage preparation, additive or enhancer for existing foods and beverages and particularly in the form of a pleasant tasting and soothing beverage.
    Type: Application
    Filed: January 10, 2017
    Publication date: October 19, 2017
    Inventors: Ron Sosenko, Donna Mascaro, Phil Parisi, George Ennis
  • Publication number: 20170296615
    Abstract: A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery, a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 19, 2017
    Inventors: Jianjun Wang, Qianqian Li
  • Publication number: 20170296616
    Abstract: This disclosure provides methods and regimens for treating depression (e.g., treatment-resistant depression) in a patient (e.g., a patient n need of such treatment).
    Type: Application
    Filed: August 13, 2015
    Publication date: October 19, 2017
    Inventor: Ron Burch
  • Publication number: 20170296617
    Abstract: The present disclosure describes peptide inhibitors of Rho-associtated-kinase (ROCK) and their use in treating disorders including heart failure, the leading cause of combined morbidity and mortality in the United States. An inhibitory polypeptide blocks ROCK1 activity in the presence of 1 mM ATP. The binding epitope on ROCK1 was mapped using chemical cross-linking to the Activation Loop, a novel locus identifying a new class of inhibitory drugs. The peptides described will be useful against a number of important diseases such as heart disease, pulmonary hypertension, arterial hypertension, gluacoma management, insulin resistance, kidney disease, hemolytic anemia, stroke, ischemia reperfusion injury, or acute mycloid leukemia.
    Type: Application
    Filed: October 1, 2015
    Publication date: October 19, 2017
    Applicant: UNIVERSITY OF HOUSTON SYSTEM
    Inventors: Robert J. SCHWARTZ, Hua ZHANG, John W. CRAFT, Scott GILBERTSON, Kevin MACKENZIE, Reza ABBASGHOLIZADEH, Steven BARK, James M. BRIGGS, Robert FOX
  • Publication number: 20170296618
    Abstract: The present application presents novel peptidomimetic substituted hydroxyethylene compounds, which are inhibitors of beta amyloid cleavage enzyme, capable to permeate the brain and to achieve therapeutic concentrations in the target organ, the brain. These compounds are incorporated in pharmaceutical compositions and applied in the treatment or prophylaxis of neurological disorders or conditions and also other disorders or conditions including Down's syndrome and diabetes.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 19, 2017
    Inventors: Helder Joao FERREIRA VILA REAL, Ana Luisa FERREIRA SIMPLICIO, Olga IRANZO CASANOVA, Christopher David MAYCOCK
  • Publication number: 20170296619
    Abstract: The present invention provides small molecule inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which are useful as therapeutics in the management of chronic HBV. The compounds of the invention achieve epigenetic modification of the cccDNA, histone modification and histone deacetylase activity inhibition, thus modulating HBV cccDNA. The present invention further provides methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject.
    Type: Application
    Filed: April 10, 2017
    Publication date: October 19, 2017
    Inventors: JU-TAO GUO, JINHONG CHANG, TIMOTHY M. BLOCK, WILLIAM A. KINNEY, HAROLD R. ALMOND
  • Publication number: 20170296620
    Abstract: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.
    Type: Application
    Filed: May 11, 2017
    Publication date: October 19, 2017
    Inventor: Huw M. Nash
  • Publication number: 20170296621
    Abstract: The present invention is directed to an agonist of NOD2 for use in therapy for increasing the autonomous capacity of survival of vertebrate adult stem cells, without loss of their capacity to multiply and differentiate, and preferably the capacity of survival of intestinal stem cells, especially in response to a stress. The invention also concerns the use of an agonist of Nod2 for increasing in vitro or ex vivo the autonomous capacity of survival, without loss of multiplication and differentiation capacity of mammalian adult stem cell. The invention also discloses different media and support for mammalian adult stem cells. The invention also concerns an in vitro screening process for identifying molecules capable increasing, in response to a stress, the autonomous capacity of survival, without loss of multiplication and differentiation capacity of mammalian adult stem cells.
    Type: Application
    Filed: April 3, 2017
    Publication date: October 19, 2017
    Inventors: Philippe Sansonetti, Giulia NIGRO
  • Publication number: 20170296622
    Abstract: The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans.
    Type: Application
    Filed: June 1, 2017
    Publication date: October 19, 2017
    Applicant: Hexima Limited
    Inventors: Nicole Louise van der Weeden, Marilyn Anne Anderson
  • Publication number: 20170296623
    Abstract: The invention relates to negative T-cell signal inducing chimeric antigen receptor (N-CAR or i-CAR) and to T-cells comprising such N-CAR as well as a positive T-cell signal inducing CAR (P-CAR) as well as their use in therapy.
    Type: Application
    Filed: December 17, 2015
    Publication date: October 19, 2017
    Inventors: Alexandre JUILLERAT, Philippe DUCHATEAU, Laurent POIROT
  • Publication number: 20170296624
    Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 19, 2017
    Applicant: Bayer HealthCare LLC
    Inventors: Maxine BAUZON, Terry HERMISTON
  • Publication number: 20170296625
    Abstract: Methods for detecting, imaging, analyzing, diagnosing and/or treating cutaneous conditions and dermatoses such as disorders of the skin, subcutaneous tissues, mucous membranes, poorly vascularized tissues and/or other tissue disorders, including erosions, fissures, transient and/or chronic sores, burns, wounds, ulcers, lesions and infections. In particular embodiments, treatments include methods for improving skin and related tissue healing and repair, offloading of damaged tissues and/or increasing angiogenesis in response to specifically diagnosed conditions.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 19, 2017
    Inventors: Vance GARDNER, Kenneth THOMAS, John JACOBS, Mickael FLAA
  • Publication number: 20170296626
    Abstract: Methods of isolating exosomes from a biological sample is provided. In one embodiment, the method may include a series of optional centrifugation steps, and comprises exosome precipitation using a PEG-based solution followed by resuspension in a saccharide-based solution such as trehalose. The method advantageously results in essentially pure exosomes that maintain integrity and stability. The exosomes are useful for the in vivo delivery of cargo, including macromolecules such as protein and nucleic acid.
    Type: Application
    Filed: March 3, 2017
    Publication date: October 19, 2017
    Inventor: Mark TARNOPOLSKY
  • Publication number: 20170296627
    Abstract: An exosome pellet or physiological solution comprising resuspended exosomes is provided. The exosomes are essentially free from undesirable particles having a diameter less than 20 nm or greater than 140 nm, and the exosomes comprise one or more metabolic products. The exosomes may be used to induce mitochondrial biogenesis, increase thermogenesis (browning) of subcutaneous white adipose tissue, and/or mediate other systemic effects of exercise in a mammal.
    Type: Application
    Filed: March 3, 2017
    Publication date: October 19, 2017
    Inventor: Mark TARNOPOLSKY
  • Publication number: 20170296628
    Abstract: Described herein are bioactive peptides that are modified at one or more positions with a PEG moiety. An example of such a PEGylated bioactive peptide is a GHRH analog that is modified at one or more positions with a PEG moiety. Also described are pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such analogs or salts thereof, as well as methods, kits and uses thereof, for example for inducing or stimulating growth hormone secretion in a subject and for diagnosing, preventing or treating GH-deficient conditions in a subject.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 19, 2017
    Inventor: KRISHNA G. PERI
  • Publication number: 20170296629
    Abstract: An object of the present invention is to provide a novel drug inhibiting extracellular trap formation in leukocytes. The present invention provides an inhibitor of extracellular trap formation in leukocytes containing a lactoferrin fragment, and a composition containing lactoferrin for treating a disease related to the extracellular trap formation in leukocytes.
    Type: Application
    Filed: October 6, 2015
    Publication date: October 19, 2017
    Applicants: KEIO UNIVERSITY, NRL PHARMA, INC.
    Inventors: Junichi HIRAHASHI, Koshu OKUBO, Hiroshi KAWAKAMI, Shinji KAGAYA
  • Publication number: 20170296630
    Abstract: The invention is directed to a more efficient lentiviral vector comprising a nucleic acid sequence encoding a human ?-globin protein or a human ?-globin protein, which is oriented from 5? to 3? relative to the lentiviral genome. The invention also provides a composition and method utilizing the lentiviral vector.
    Type: Application
    Filed: August 14, 2015
    Publication date: October 19, 2017
    Applicant: The United State of America, as represented by the Secretary, Department of Health and Human Service
    Inventors: Naoya Uchida, John F. Tisdale
  • Publication number: 20170296631
    Abstract: The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 19, 2017
    Inventors: Gregory A. Grabowski, Hong Du
  • Publication number: 20170296632
    Abstract: The invention relates to a drink includes angiogenin and/or angiogenin hydrolysate in an amount of more than 0.8 mg/100 ml and not more than 150 mg/100 ml, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.
    Type: Application
    Filed: July 3, 2017
    Publication date: October 19, 2017
    Applicant: MEGMILK SNOW BRAND CO., LTD.
    Inventors: Aiko OHMACHI, Hiroaki MATSUYAMA, Yoshikazu MORITA, Yuko ISHIDA, Takayuki NARA, Ken KATO, Atsushi SERIZAWA, Hiroshi UENO, Hiroshi URAZONO
  • Publication number: 20170296633
    Abstract: The invention provides compositions and methods for treating celiac sprue.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 19, 2017
    Inventors: Justin SIEGEL, David BAKER, Sydney Rin Anna GORDON, Ingrid Swanson PULTZ, Elizabeth Joy STANLEY, Sarah Jane WOLF
  • Publication number: 20170296634
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 19, 2017
    Inventor: Ulla Hedner
  • Publication number: 20170296635
    Abstract: Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Application
    Filed: January 25, 2017
    Publication date: October 19, 2017
    Inventors: Leslie Ann Greene, Ryan Andrew Adams, Fei Hong, Ji Zhao, Eva Rebecka Stephanie Armour, Kristi Helen Piehl
  • Publication number: 20170296636
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Application
    Filed: September 19, 2015
    Publication date: October 19, 2017
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Publication number: 20170296637
    Abstract: The present specification discloses Trypanosoma antigens, immunogenic compositions and medicaments comprising such Trypanosoma antigens, methods and uses for such Trypanosoma antigens and immunogenic compositions for treating a Trypanosoma-based disease.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 19, 2017
    Applicant: PepTcell Limited
    Inventors: Olga Pleguezuelos Mateo, Wilson Caparros-Wanderley, Gregory A. Stoloff
  • Publication number: 20170296638
    Abstract: The present invention is directed to a preparation of an adjuvant system to achieve required level of humoral and cellular immune response against antigen of interest. The current invention provides an adjuvant system comprising an immunostimulating reconstituted influenza virosomes (IRIVs) and immunopotentiators. The current invention illustrates that an antigen is adsorbed or incorporated into IRIVs and further formulated with lipophilic adjuvant such as MPL or glucopyranosyl lipid adjuvant (synthetic analogue of MPL).
    Type: Application
    Filed: September 1, 2015
    Publication date: October 19, 2017
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Gaurav GUPTA, Epifanio FICHERA, Reinhard GLUECK
  • Publication number: 20170296639
    Abstract: The present invention provides a method for preparing dendritic cell loaded with antigen, the method comprising the steps of adding serum-free cell culture medium containing granulocyte-macrophage colony-stimulating factor (GM-CSF) and inter-leukin (IL)-4 into mononuclear cells, culturing in an incubator at 37° C. under 5% carbon dioxide for 5 days, adding target antigen wrapped cationic liposome and culturing for 8-24 hours to obtain target antigen loaded dendritic cell.
    Type: Application
    Filed: May 20, 2015
    Publication date: October 19, 2017
    Inventors: Yifan MA, Xiangjun ZHOU, Shang CHEN, Lintao CAI, Ce WANG, Peng LIU
  • Publication number: 20170296640
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: February 17, 2017
    Publication date: October 19, 2017
    Inventors: Oliver SCHOOR, Andrea MAHR, Toni WEINSCHENK, Anita WIEBE, Jens Fritsche, Harpreet SINGH
  • Publication number: 20170296641
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate antitumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: March 16, 2017
    Publication date: October 19, 2017
    Inventors: TONI WEINSCHENK, OLIVER SCHOOR, ANDREA MAHR
  • Publication number: 20170296642
    Abstract: Disclosed is an antitumor vaccine including testicular and fetal tissue-derived components. Cell preparations are prepared from normal tissues harvested directly from animals. Such vaccines may be used in the treatment and prevention of different cancers. For example, a vaccine consisting of glutaraldehyde-treated cells prepared from sheep testis and fetal lung has been found to be effective in inducing antitumor cell-mediated responses, as well as in prolonging the survival of mice with lung cancer.
    Type: Application
    Filed: April 15, 2015
    Publication date: October 19, 2017
    Inventors: Victor I. SELEDTSOV, Galina V. SELEDTSOVA, Adas DARINSKAS
  • Publication number: 20170296643
    Abstract: The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in SEQ ID NO:8 or a protein having at least 80% similarity thereto.
    Type: Application
    Filed: December 5, 2016
    Publication date: October 19, 2017
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Laura SERINO, Mariagrazia PIZZA
  • Publication number: 20170296644
    Abstract: Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.
    Type: Application
    Filed: April 18, 2017
    Publication date: October 19, 2017
    Inventors: Ashok K. Chopra, Vladimir L. Motin, Eric Rothe
  • Publication number: 20170296645
    Abstract: The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS)
    Type: Application
    Filed: June 22, 2017
    Publication date: October 19, 2017
    Inventors: Guido Grandi, Domenico Maione, Cira Daniela Rinaudo
  • Publication number: 20170296646
    Abstract: Novel attenuating deletions of Zika virus E2 polypeptides are provided as are attenuated viruses comprising the deletions. Also provided are immunogenic compositions that comprise the attenuated viruses and methods of producing such viruses in cells (such as insect cells). Viruses of the embodiments can be used for immunization of animals to provide protection from the pathogenic effects of Zika virus infection.
    Type: Application
    Filed: March 28, 2017
    Publication date: October 19, 2017
    Inventors: Raquel HERNANDEZ, Dennis T. BROWN
  • Publication number: 20170296647
    Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 19, 2017
    Inventors: Jamie SULLEY, Luis SQUIQUERA, David SIDRANSKY, Tom HODGE
  • Publication number: 20170296648
    Abstract: The present invention pertains to a vaccine for use in protecting offspring of a sow against an infection with porcine endemic diarrhea virus (PEDV), the vaccine comprising non-live PEDV antigen and an oil containing adjuvant, by administration of the vaccine to the pregnant sow at a dose of the antigen corresponding to at least 3.0E6 TCID50 killed whole PEDV. The invention also pertains to a method of protecting young piglets against an infection with porcine endemic diarrhea virus (PEDV).
    Type: Application
    Filed: September 11, 2015
    Publication date: October 19, 2017
    Applicants: Intervet Inc., Universiteit Utrecht Holding B.V.
    Inventors: Erwin Born, van den, Berend Jan Bosch, Peter Rottier
  • Publication number: 20170296649
    Abstract: Provided is a method for inducing T cells for a cell-based immunotherapy, which comprises the steps of: (1) providing human pluripotent stem cells bearing a T cell receptor specific for a desired antigen, and (2) inducing T cell progenitors or mature T cells from the pluripotent stem cells of step (1). Especially, a method for inducing T cells for a cell-based immunotherapy from cells of a person who is not the subject to be treated by the cell-based immunotherapy. The method provided herein may further comprise a step of co-culturing the T cell progenitors or mature T cells induced from the pluripotent stem cells with the lymphocytes of the subject to be treated by the cell based immunotherapy to verify that the T cells are not allogenicaly reactive against the subject.
    Type: Application
    Filed: July 17, 2015
    Publication date: October 19, 2017
    Inventor: Hiroshi KAWAMOTO
  • Publication number: 20170296650
    Abstract: The disclosure relates to the use of a combination of antibodies or antigen binding fragments thereof to hCMV; and to dosages, ratios and minimum trough serum concentrations of the antibodies. The combination is useful for the neutralization of hCMV, for example, in pregnant, immunocompromised or immunosuppressed patients undergoing bone marrow and organ transplants with a low occurrence of viral resistance.
    Type: Application
    Filed: October 7, 2015
    Publication date: October 19, 2017
    Inventors: Adam FEIRE, Yinuo PANG, Peter PERTEL, Jing YU
  • Publication number: 20170296651
    Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.
    Type: Application
    Filed: February 24, 2015
    Publication date: October 19, 2017
    Applicant: BTG International Limited
    Inventors: Robert Anderson, Tim Beissbath, Jason Tye Din
  • Publication number: 20170296652
    Abstract: This disclosure describes recombinant hypoallergens and methods of treating allergy that involve administering a recombinant hypoallergen to a subject. Generally, the recombinant hypoallergen includes at least one amino acid modification compared to a corresponding wildtype allergen. As a result, the recombinant hypoallergen binds to IgE that specifically binds to the allergen, but induces release of histamine from basophils to a degree less than the wildtype allergen.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 19, 2017
    Inventors: Bridget S. Wilson, Diane Lidke, Lydia Tapia, Mark Schulyer, Avanika Mahajan
  • Publication number: 20170296653
    Abstract: Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating Kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an IL-10 agent are also provided.
    Type: Application
    Filed: May 6, 2015
    Publication date: October 19, 2017
    Inventors: John Brian Mumm, Ivan Ho Chan
  • Publication number: 20170296654
    Abstract: The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
    Type: Application
    Filed: July 3, 2017
    Publication date: October 19, 2017
    Inventors: Mariusz BANASZCZYK, Normand HÉBERT, Neil STOWE
  • Publication number: 20170296655
    Abstract: Cyclic-GMP-AMP (cGAMP), including 2?,3?-cGAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.
    Type: Application
    Filed: January 29, 2017
    Publication date: October 19, 2017
    Applicant: Board of Regents, The University of Texas System
    Inventors: Zhijian CHEN, Lijun SUN, Jiaxi WU, Heping SHI, Chuo CHEN
  • Publication number: 20170296656
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Application
    Filed: March 27, 2017
    Publication date: October 19, 2017
    Applicant: Valneva Austria GmbH
    Inventors: ROBERT SCHLEGL, Michael Möhlen, Jürgen Wruss, Michael Weber
  • Publication number: 20170296657
    Abstract: The present invention provides methods for treating hypercholesterolemia and reducing LDL-C. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 19, 2017
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald, Gary Swergold, Robert C. Pordy, William J. Sasiela
  • Publication number: 20170296658
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Application
    Filed: February 24, 2017
    Publication date: October 19, 2017
    Inventor: Austin L. GURNEY
  • Publication number: 20170296659
    Abstract: Disclosed is a combination comprising an immunomodulator and a second therapeutic agent for use in treating cancer, wherein the immunomodulator is an inhibitor of an immune checkpoint molecule or an activator of a costimulatory molecule, or a combination thereof; and the second therapeutic agent is chosen from one or more of: 1) a c-MET inhibitor; 2) a CDK4/6 inhibitor; 3) a PI3K inhibitor; 4) a BRAF inhibitor; 5) an FGFR inhibitor; 6) a MEK inhibitor, or 7) a BCR-ABL inhibitor. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.
    Type: Application
    Filed: September 11, 2015
    Publication date: October 19, 2017
    Inventors: David Lebwohl, Malte Peters
  • Publication number: 20170296660
    Abstract: This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided.
    Type: Application
    Filed: May 2, 2017
    Publication date: October 19, 2017
    Applicant: Mayo Foundation for Medical Education and Research
    Inventor: Isobel A. Scarisbrick
  • Publication number: 20170296661
    Abstract: The present application relates to activable nanoparticles which can be used in the health sector, in particular in human health, to disturb, alter or destroy target cells, tissues or organs. It more particularly relates to nanoparticles which can generate a significantly efficient therapeutic effect, when exposed to ionizing radiations. The inventive nanoparticle is a metallic nanoparticle having, as the largest size, a size comprised between about 80 and 105 nm, the metal having preferably an atomic number (Z) of at least 25. The invention also relates to pharmaceutical compositions comprising a population of nanoparticles as defined previously, as well as to their uses.
    Type: Application
    Filed: June 28, 2017
    Publication date: October 19, 2017
    Inventors: LAURENT LEVY, AGNES POTTIER, LAURENCE POUL, LAURENCE MAGGIORELLA